Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Initial micafungin treatment does not improve outcomes compared to fluconazole treatment in immunocompromised and critically ill patients with candidaemia

Journal of Antimicrobial Chemotherapy(2024)10.1093/jac/dkae175Source: DataRank Database

Initial micafungin treatment does not improve outcomes compared to fluconazole treatment in immunocompromised and critically ill patients with candidaemia is a research paper published in Journal of Antimicrobial Chemotherapy (2024). On theSindex it has a DataRank of 0. It has been cited 4 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access4 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (9 grants)Impact (FWCI 0.64)OA: greenTopics (63)IDs (PubMed, PMC, OpenAlex)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (7)

Amrita D Henneman,Angela Loo,Ryan K. Shields ORCID,Gregory Eschenauer ORCID,Magdalena E. Sobieszczyk ORCID

Live enrichment

PubMed:38831614 PMC:PMC11290885 OpenAlex:https://openalex.org/W4399327298

National Institutes of Health

Grant: 5UM1AI069470-18

Columbia Collaborative HIV/AIDS Clinical Trials Unit

National Institutes of Health

Grant: UL1TR001873

NCI

Grant: P30CA013696

NIAID NIH HHS

Grant: UM1 AI069470

National Institute of Allergy and Infectious Diseases

NIH

National Center for Advancing Translational Sciences

National Institute of Allergy and Infectious Diseases

NIH

FWCI

0.64

Citation Percentile

0.6%

Citation Trend

2025

greenLicense: OUP Standard Publication Reuse

repositoryhttps://pmc.ncbi.nlm.nih.gov/articles/PMC11290885/pdf/dkae175.pdf

publisherhttps://academic.oup.com/jac/article-pdf/79/8/1877/58688994/dkae175.pdf

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/11290885

journalhttps://doi.org/10.1093/jac/dkae175

Fields of Study

Immunodeficiency and Autoimmune DisordersAntifungal resistance and susceptibilityAdrenal Hormones and Disorders0301 basic medicine0303 health sciences03 medical and health sciencesHumansMicafunginAntifungal AgentsMaleRetrospective StudiesFemaleMiddle AgedCritical IllnessImmunocompromised HostTreatment OutcomeCandidemiaAgedFluconazoleEchinocandinsAdultLipopeptidesSurvival Analysis

MeSH Terms

MicafunginAdultAgedAntifungal AgentsFemaleHumansMaleMiddle AgedRetrospective StudiesFluconazoleSurvival AnalysisCritical IllnessImmunocompromised HostTreatment OutcomeEchinocandinsLipopeptidesCandidemia

Keywords

EchinocandinMicafunginFluconazoleCritically illMedicineIntensive care medicineInvasive candidiasisCritical illnessAntifungalMaleAdultAntifungal AgentsCandidemiaMiddle AgedSurvival AnalysisImmunocompromised HostEchinocandinsLipopeptidesTreatment OutcomeHumansFemaleRetrospective StudiesAged

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being